Research and development work is underway into a novel gene therapy employing cutting edge nano-technology which, we believe, may have the potential to treat several forms of cancer. Ryboquin ECP-102 is a Tumour Apoptosis Enhancer (TAE). This new class of drugs is designed to make chemotherapy many times more effective.
A Phase 1 study in cancer patients will be launched in 2015. We intend to progress the project to a successful conclusion of Phase 2 trials before seeking a partner to join us in taking the product onto the market.
Download the brochure below to read the full story.